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 SATU KAJIAN LIPOSOM UNTUK PENGHANTARAN SECARA ORAL SATU 
DRUG MODEL BERBIOKEPEROLEHAN RENDAH: GRISEOFULVIN 
 
ABSTRAK  
 
Potensi formulasi liposom sebagai sistem penghantaran drug untuk 
pengambilan oral drug-drug berbiokeperolehan rendah telah dikaji 
menggunakan griseofulvin sebagai drug model. Satu teknik ekstrusi 
menggunakan alat yang dipasang sendiri telah dinilai untuk menano-saizkan 
liposom. Saiz partikel dan taburan saiz liposom yang dihasilkan dipengaruhi 
oleh pelbagai parameter pemprosesan. Namun demikian, kaedah ektrusi 
adalah ringkas, mudah dihasilkan semula dan lebih berkesan berbanding 
dengan kaedah pengurangan saiz lain yang dinilai. Kajian in vitro 
menunjukkan bahawa liposom yang disediakan daripada pelbagai pra-
liposom, iaitu Pro-lipo duo®, Pro-lipo C® dan Pro-lipo S® semuanya 
mempunyai saiz berjulat nanometer dengan taburan saiz kecil. Liposom yang 
disediakan daripada Pro-lipo duo® mempunyai saiz yang paling kecil dan 
adalah paling stabil berbanding dengan pro-liposom yang lain. Kecekapan 
pemerangkapan griseofulvin dalam liposom dapat ditingkatkan dengan 
meningkatkan tempoh penyebatian dan suhu ataupun menggunakan pelarut-
pelarut organik sebagai alat bantu pemelarutan. Pemerangkapan tertinggi 
griseofulvin telah dicapai dengan Pro-lipo duo® menggunakan kloroform 
sebagai alat bantu pemelarutan dan oleh itu, ia telah dipilih untuk penilaian in 
vivo yang seterusnya. Kajian perbandingan biokeperolehan in vivo 
mendedahkan bahawa biokeperolehan oral griseofulvin boleh ditingkatkan 
 sebanyak 2.7-3.2 kali apabila menggunakan liposom, akan tetapi, amaun 
drug yang terperangkap dalam liposom adalah penting untuk meningkatkan 
penyerapan sistemik. Walau bagaimanapun, peningkatan biokeperolehan 
griseofulvin dalam formulasi liposom yang diperolehi bukan disebabkan oleh 
promosi pengangkutan limfatik drug. Tambahan itu, saiz liposom didapati 
mempengaruhi takat biokeperolehan tetapi tidak menjejaskan tempoh 
penyerapan griseofulvin. Namun demikian, penyerapan atau biokeperolehan 
liposom didapati menjadi sama cekap untuk liposom-liposom bersaiz di 
bawah 400nm, di mana, pengurangan saiz liposom yang selanjutnya 
mempunyai kesan terhad ataupun tiada impak selanjutnya pada takat 
biokeperolehan. Berdasarkan penemuan-penemuan kajian ini, boleh 
disimpulkan bahawa liposom mempunyai potensi untuk menjadi satu sistem 
penyampaian drug yang berkesan untuk pengambilan oral drug-drug 
berketerlarutan air rendah, yang tanpa liposom adalah berbiokeperolehan 
rendah. 
 AN INVESTIGATION OF LIPOSOMES FOR ORAL DELIVERY OF A 
POORLY BIOAVAILABLE MODEL DRUG: GRISEOFULVIN 
 
ABSTRACT 
 
The potential of liposomal formulation as a drug delivery system for oral 
administration of poorly bioavailable drugs was studied using griseofulvin as 
the model drug. An extrusion technique using a self-assembled instrument 
was evaluated for nanosizing the liposomes. The particle size and size 
distribution of liposomes produced was affected by various processing 
parameters. Nevertheless, the extrusion method was simple, reproducible 
and more effective compared to other size-reduction methods evaluated. In 
vitro studies showed that liposomes prepared from various pro-liposomes, 
namely Pro-lipo duo®, Pro-lipo C® and Pro-lipo S® were all in nanometer size 
range with a narrow size distribution. Liposomes prepared from Pro-lipo duo® 
were smallest in size and most stable compared to other pro-liposomes. The 
encapsulation efficiency of griseofulvin-loaded liposomes could be enhanced 
by increasing the mixing duration and temperature or using organic solvents 
as solubilisation aids. The highest encapsulation of griseofulvin was achieved 
with Pro-lipo duo® using chloroform as the solubilisation aid and hence, it was 
selected for further in vivo evaluations. The in vivo comparative bioavailability 
study revealed that the oral bioavailability of griseofulvin could be increased 
by 2.7 to 3.2 times using liposomes but the amount of drug encapsulated in 
the liposomes was important for enhancing the systemic absorption. 
However, the enhanced bioavailability of griseofulvin in liposomal 
formulations obtained was not due to the promotion of lymphatic drug 
 transport. In addition, the size of liposomes was found to affect the extent of 
bioavailability but has no influence on the duration of griseofulvin absorption.  
Nonetheless, the uptake or bioavailability of liposomes was found to be 
equally efficient with liposomes below 400nm, whereby, a further size 
reduction in the liposomes has limited or no further impact on the extent of 
bioavailability. On the basis of the findings of this study, it was concluded that 
liposomes have the potential of being an effective drug delivery system for 
the oral administration of poorly soluble drugs that are otherwise poorly 
bioavailable orally. 
 
 CHAPTER 1  INTRODUCTION 
 
1.1 BIOAVAILABILITY 
1.1.1 INTRODUCTION 
The concept of bioavailability, at first called physiological availability, was first 
introduced in 1945  during the studies of relative absorption of vitamins from 
pharmaceutical products (Oser et al., 1945). Over the years, the multiplicity of 
terms used to describe bioavailability had caused considerable ambiguity 
among the researchers. Confusion has arisen over the interchangeability of 
the terms used, namely, biologic availability (bioavailability), physiologic 
availability, generic equivalence and therapeutic equivalence (Wagner, 
1975b). After much reviews and debates, bioavailability eventually became 
the mutually accepted term. 
 
 
1.1.2 DEFINITION 
The U.S. Food and Drug Administration (FDA) defines bioavailability as the 
rate and extent in which the active ingredient or active moiety is absorbed 
from a drug product and becomes available at the site of action (Chen et al., 
2001). Since measurement of the drug concentration at the site of action is 
not always feasible, the bioavailability is more commonly defined as the rate 
and extent of which an active drug is absorbed from a dosage form and 
becomes available in the systemic circulation. 
 
 1.1.3 BARRIERS AFFECTING ORAL BIOAVAILABILITY OF POORLY 
WATER SOLUBLE DRUGS 
The oral route has remained the preferred mode of drug administration, 
mainly due to its convenience and better patient compliance. However, poorly 
water-soluble drugs suffer low bioavailability when administered orally 
(Dahan and Hoffman, 2008, Humberstone and Charman, 1997). Various 
absorption barriers have been known to affect the oral bioavailability of these 
drugs (Figure 1.1). They can be categorized into pre-enterocyte, enterocyte 
and post-enterocyte barriers (Dahan and Hoffman, 2007a).  
 
1.1.3(a) PRE-ENTEROCYTE BARRIERS 
i) SOLUBILITY 
Following oral administration, dissolution of the drug molecule in the intestinal 
milieu is a prerequisite for the absorption process. If the drug is insoluble or 
poorly water-soluble, it poses a problem of poor dissolution and/or 
absorption, since the flux of a drug across the intestinal membrane is 
proportional to its concentration gradient between the apical side and 
basolateral sides of gastrointestinal (GI) lumen (Panchagnula and Thomas, 
2000).   
 
According to the Biopharmaceutics Classification System (BCS) (Amidon et 
al., 1995), poorly water-soluble compounds (with solubility less than 
100µg/mL) are classified as either class II or class IV compounds, depending 
on their intestinal permeability. For BCS class II drugs that exhibit high 
permeability characteristics, drug absorption is governed by their dissolution 
 in the GI fluids. Whereas, BCS class IV drugs, characterized by both low 
solubility and poor intestinal wall permeability, are generally poor drug 
candidates for oral administration. 
 
The aid of surfactants provided by biliary secretions is necessary to solubilize 
the poorly water-soluble drug and to enable its absorption (Dahan and 
Hoffman, 2008). These biliary secretions help by forming submicron mixed 
micelles with the drug and hence enable the solubilized drug to reach the 
absorptive membrane of the enterocyte. Limited in its capacity and 
considerably variable in different situations, this process is the rate-limiting 
step in the absorption of the poorly water-soluble drugs and often becomes a 
significant absorption barrier (Dahan and Hoffman, 2007a). 
 
ii) LIMITED ABSORPTION SITE 
The absorption of the poorly water-soluble drugs usually takes place along 
the small intestine, where drug solubilization occurs. The residence time of a 
drug in the upper GI tract has been shown to be relatively short and the 
transit time along the small intestine is about 3.0-4.5 hours in healthy 
volunteers (Yu and Amidon, 1999). Although fat can prolong the small 
intestinal transit time (by 30-60 minutes), it is not thought to be of any 
significance in drug delivery (Dahan and Hoffman, 2007a). As a result, the 
absorption of a poorly water-soluble drug may be poor due to limited site of 
absorption, and if the drug reaches the colon prior to solubilization, its 
bioavailability is expected to be even lower. 
 
  
 
 
Figure 1.1 Barriers affecting oral bioavailability of poorly water-soluble drugs 
(adapted from Dahan and Hoffman, 2008)  
 
 
 
 
 
 
 
 
 
 iii) UNSTIRRED WATER LAYER 
The unstirred layer refers to the stagnant layer of water adjacent to the 
absorptive membrane of the enterocyte (Ashford, 2002). It can be visualized 
as a series of water lamellas, each progressively more stirred from the gut 
wall toward the lumen bulk (Dahan and Hoffman, 2008). For BCS class II 
drugs, the rate of permeation through the brush border is fast due to large 
surface area and thus the diffusion across the unstirred water layer (UWL) 
becomes the rate-limiting step in the permeation process. A study by Read et 
al. (1977) found that the thickness of the UWL in human jejunum is over 
500µm. Due to its thickness and hydrophilicity, the UWL may represent a 
major permeability barrier to the absorption of poorly water-soluble drugs. In 
addition, the effective surface area of the UWL also plays a role in limiting 
drug absorption. The ratio of the surface area of the UWL to that of the 
underlying brush border membrane is at least 1:500 (Westergaard and 
Dietschy, 1974). This low ratio value suggests that the effective surface area 
of the UWL available for the absorption of poorly water-soluble drugs is 
relatively small, and hence, their bioavailability are impaired. 
 
1.1.3(b) ENTEROCYTE BARRIERS 
Upon entering the enterocyte, a drug molecule faces another set of 
biochemical barriers that affect the magnitude of its absorption. The 
cytochrome P450 3A4 (CYP3A4) enzymes, located in the endoplasmic 
reticulum of the enterocyte, are responsible for most drug metabolism in the 
intestinal wall. A study by Wacher et al. (1998) found that this isoenzyme 
accounted for more than 70% of all small intestinal CYP450s. While some 
 transporters located in the apical wall of the enterocyte facilitate absorption, 
there are others that serve as efflux transporters. Efflux transporters play a 
major role in the disposition of many drugs, and thus, are regarded as the 
multiple drug resistance (MDR) transporters. The apical P-glycoprotein (P-gp) 
efflux pump is the most extensively studied MDR transporter. It reduces the 
fraction of drug absorbed by transporting the drug from the enterocyte back 
to the intestinal lumen (Gottesman et al., 1996). 
 
Synergism exists between the activity of the metabolic CYP3A4 enzymes and 
the P-gp system. A drug molecule that escapes the intra-enterocyte 
metabolism may either reach the blood circulation or be effluxed back into the 
GI lumen, and then may be reabsorbed (Benet and Cummins, 2001). Many 
studies have shown that these two pre-hepatic systems contributed to the 
limited oral bioavailability of many poorly water-soluble drugs (Lennernäs, 
2003, Fitzsimmons and Collins, 1997, Thummel et al., 1996, Kolars et al., 
1991). 
 
1.1.3(c) POST-ENTEROCYTE BARRIERS 
A drug molecule that manages to escape the intra-enterocyte metabolism 
and the MDR efflux systems will diffuse across the cell and be secreted from 
the basolateral membrane of the enterocyte into the lamina proporia. 
Following that, the drug is usually absorbed into the portal blood unless it is 
being incorporated into a chylomicron. However, before reaching the 
systemic blood circulation, the drug molecules will have to pass through the 
liver, and hence are exposed to the metabolic enzymes. This first-pass 
 hepatic metabolism has been shown to be a major barrier to the absorption of 
poorly water-soluble drugs, which are the most likely molecules to undergo 
oxidative metabolism. 
 
 
1.1.4 APPROACHES TO ENHANCE THE ORAL BIOAVAILABILITY OF 
POORLY WATER-SOLUBLE DRUGS 
Low oral bioavailability of poorly water-soluble drugs poses a great challenge 
during drug development (Lipinski et al., 1997). Various approaches have 
been developed to improve the bioavailability by increasing the drug 
dissolution rate and solubility.  A summary of the strategies and approaches 
is detailed in the following sections.  
 
1.1.4(a) PRODRUGS  
The term prodrug may be defined as a chemical derivative of a drug that is 
bioconvertible into the active parent drug or an active metabolite responsible 
for the therapeutic effect (Kim and Singh, 2002). Prodrugs are formed by 
attachment of the active drug through a metabolically labile linkage to another 
molecule, the “promoiety‟, to impart some desirable properties to the drug. 
Chloramphenicol for example, was chemically modified to produce a prodrug, 
chloramphenicol sodium succinate with enhanced solubility. As a result of 
this modification, its aqueous solubility was improved significantly from 2.5 
mg/ml to 100 mg/ml  (Maurin et al., 2002). Besides that, prodrugs can be 
designed to improve the bioavailability via other means. L-Dopa for instance 
improved the bioavailability of dopamine by overcoming the blood-brain 
 barrier; whereas, propanolol hemisuccinate blocked the formation of 
glucuronide which resulted in a reduction of the first-pass metabolism to 
increase the bioavailability of propanolol (Anderson et al., 1988). 
 
1.1.4(b) COMPLEXATION 
Cyclodextrins have been extensively utilized as complexing agents to 
improve the bioavailability of numerous poorly water-soluble drugs (Figeiras 
et al., 2007, Larsen et al., 2005, Green and Guillory, 1989). The cyclic 
oligosaccharides obtained from the enzymatic degradation of starch have a 
unique structure of an apolar cavity and a hydrophilic external part, which 
renders them to mask the physicochemical properties of the included drug 
molecule. The mechanism of bioavailability enhancement by cyclodextrins 
complexation has been attributed to the improvement of solubility, dissolution 
rate and chemical stability (Loftsson and Brewster, 1996). In addition to the 
inclusion of complexes formed by cyclodextrins, other types of molecular 
complexes, such as caffeine, sodium salicylate, sodium benzoate and 
nicotinamide have also been reported.  
 
1.1.4(c) COSOLVENT APPROACH 
A cosolvent is a water-miscible organic solvent that is used to increase 
aqueous solubility of a poorly water-soluble compound or to increase the 
chemical stability of a drug. Due to their low toxicity, ethanol, glycerol and 
polyethylene glycols (PEGs), are commonly selected for formulating poorly 
water-soluble drugs (Strickley, 2004). In a recent study, the cosolvent 
technique used for the preparation of carbamazepine nanosuspensions not 
 only increased the aqueous solubility of carbamazepine but also improved 
the stability of the formulations (Douroumis and Fahr, 2007).   
 
1.1.4(d) PARTICLE SIZE REDUCTION 
The dissolution rate of a drug can be proportionally increased by increasing 
its surface area as a consequence of comminution. The bioavailability of the 
antifungal, griseofulvin, was enhanced significantly by micronization and 
hence the effective dose was reduced by 50% (Atkinson et al., 1962). 
Absorption of naproxen was faster and the plasma levels were higher when 
the drug was administered orally (to rats) as nanoparticles, compared to that 
administered as conventional drug particles (Liversedge and Conzentino, 
1995). Besides that, several studies with a number of poorly water-soluble 
drugs, such as cilostazol, danazol and cyclosporine, have also demonstrated 
that particle size reduction can lead to an increased rate of dissolution and 
improved oral bioavailability (Jinno et al., 2006, Liversidge and Cundy, 1995, 
Tarr and Yalkowsky, 1989). Therefore, nano-sized particles are now being 
considered to boost absorption of poorly water-soluble drugs. 
 
1.1.4(e) PHARMACEUTICAL SALTS 
Salt formation is a simple means to alter the biopharmaceutical properties of 
a drug substance, particularly useful to enhance drug solubility. Salt 
formation increases drug solubility by keeping the pH at which the drug is 
ionized (Perumal and Podaralla, 2008). Numerous studies have shown that 
the solubility of poorly water-soluble drugs such as piroxicam (Gwak et al., 
 2005), meloxicam (Han and Choi, 2007) and diclofenac (O'Connor and 
Corrigan, 2001) could be enhanced via salt formation.  
 
1.1.4(f) LIPID-BASED FORMULATIONS  
The use of lipid as a potential formulation strategy for improving the oral 
bioavailability of poorly water-soluble drugs has generated much academic 
and commercial interest. Lipid-based formulations of poorly water-soluble 
drugs offer a large versatility for oral administration as they can be formulated 
as solutions, gels, suspensions, emulsions, self-emulsifying systems, 
liposomes and solid dispersions (Gershanika and Benita, 2000, Pouton, 
2000). The role of liposomes in oral delivery of poorly water-soluble drugs will 
be reviewed in section 1.3.  
 
Incorporation of the poorly water-soluble drugs into inert lipid vehicles could 
enhance the absorption and oral bioavailability via a combination of various 
mechanisms that are described in the following section. All these 
mechanisms could help to improve the oral bioavailability of drugs.  
 
 
 1.2 MECHANISMS OF LIPID-BASED FORMULATIONS IN ENHANCING 
THE ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE 
DRUGS 
The ability of lipid vehicles to enhance the bioavailability of poorly water-
soluble drugs has been well known for many years. The presentation of the 
poorly water-soluble drug as a solution in oil, avoiding the complexities 
associated with solid state, is a major factor for this bioavailability 
enhancement (Dahan and Hoffman, 2008). The other mechanisms by which 
lipid based delivery systems enhance the bioavailability of poorly water-
soluble drugs include: 
 
i) Enhanced dissolution / solubilization 
The presence of lipids in the GI tract stimulates an increase in the secretions 
of bile salts (BS) and endogenous biliary lipids such as phospholipids (PL) 
and cholesterol (Fleisher et al., 1999). These biliary products, along with the 
gastric shear movement, form crude emulsion which promotes the 
solubilization of the coadministered poorly water-soluble drug (Tso, 1985). In 
addition, the exogenous lipidic component of the delivery system is subjected 
to enzymatic digestion. Esters are rapidly hydrolyzed in the presence of 
pancreatic lipase and the lipolytic products, upon interaction with BS or PL, 
form different micellar species that prevent precipitation of the 
coadministered poorly water-soluble drug (Dahan and Hoffman, 2008). 
 
 ii) Prolongation of gastric residence time 
Lipids in the GI tract delay gastric emptying and thereby increasing the 
gastric transit time. As a result, the residence time of the coadministered 
poorly water-soluble drug in the small intestine is prolonged. This enables 
longer exposure of the drug at the absorptive site, and thereby improves its 
absorption (Hunt and Knox, 1968). 
 
iii) Stimulation of lymphatic transport 
Bioavailability of poorly water-soluble drugs may be enhanced also by the 
stimulation of the intestinal lymphatic transport pathway. Further discussions 
are in section 1.2.2. 
  
iv) Influence of  intestinal permeability 
Various combinations of lipids, lipid digestion products and surfactants have 
been shown to possess permeability enhancing properties (Aungst, 2000). In 
most instances, however, passive intestinal permeability is not thought to be 
a major barrier to the bioavailability of lipophilic drugs (Porter and Charman, 
2001a). 
 
v) Reduced metabolism and efflux activity 
Certain lipids and surfactants have been shown to reduce the activity of the 
efflux transporters in the GI wall, and hence, increase the fraction of drug 
absorbed (Dintaman and Silverman, 1999). Because synergism exists 
between the activity of P-gp and CYP3A4, these lipids and surfactants may 
also reduce the intra-enterocyte metabolism (Dahan and Hoffman, 2008). 
 1.2.1 DIGESTION AND ABSORPTION OF LIPIDS FROM 
GASTROINTESTINAL TRACT 
As mentioned in section 1.2, lipid-based formulations can reduce the inherent 
limitation of slow and incomplete dissolution of poorly water-soluble drugs, 
and facilitate the formation of solubilized phases from which absorption may 
occur. The attainment of a solubilized phase will not necessarily arise directly 
from the administered lipid, but most likely from the intraluminal processing to 
which lipids are subjected prior to absorption (Humberstone and Charman, 
1997, MacGregor et al., 1997). Therefore, an understanding of lipid digestion 
and the manner by which it contributes to drug solubilization is vital to the 
design of lipid-based formulations. 
 
The lipid digestion and absorption process, and its direct association with 
lymphatic transport of lipophilic drugs, has been extensively reviewed 
(Humberstone and Charman, 1997, Porter and Charman, 1997, Tso, 1985, 
Carey et al., 1983).  Firstly, lingual and gastric lipases initiate hydrolysis of a 
limited amount of triglyceride (TG), forming the corresponding diglyceride 
(DG) and fatty acid (FA) within the stomach. These amphiphilic lipid digestion 
products, in combination with the shear mixing produced by antral 
contraction, retropulsion and gastric emptying, facilitate the formation of a 
crude emulsion which empties into the duodenum. In duodenum, the 
emulsion induces the secretion of bile salts, biliary lipids and pancreatic fluids 
into the duodenum. Biliary lipids adsorb onto the surface of the emulsified 
lipids, improving the colloidal stability and further reducing their particle size 
(Carey et al., 1983). Subsequently, the hydrolysis of the emulsified lipids 
 takes place under the action of pancreatic lipase. This interfacial enzyme 
which requires co-lipase and bile salts to be active, acts at the surface of the 
emulsified TG droplets to quantitatively produce the corresponding 2-
monoglyceride (MG) and two molecules of  FA. 
 
Polar digestion products such as short-chain and medium-chain FAs diffuse 
across the mucosa lining of the enterocyte and enter into the portal 
circulation (Kiyasu et al., 1952). On the other hand, the non-polar digestion 
units such as the long-chain FAs (more than 12 carbons) and MG are 
emulsified by bile salts to form micelles. Micelles are not absorbed intact. The 
lipid monomers dissociate from the micelles and are subsequently absorbed 
from a monomolecular inter-micellar phase (Westergaard and Dietschy, 
1976). In addition to passive uptake, long-chain FAs and their substrates may 
utilize an enterocyte-based carrier system, called the microvillus membrane 
fatty acid binding protein (MVM-FABP)  (Stremmel, 1988, Stremmel et al., 
1985). Once inside the cell, the long-chain FAs are re-esterified to form 
triglycerides, which are incorporated into lipoproteins to form chylomicrons 
(Davidson, 1994). The chylomicrons cannot permeate the blood capillaries 
due to its large particle size (200-800µm) (Dahan and Hoffman, 2007a). 
Thus, they are absorbed into a porous mesenteric lymph vessel called lacteal 
and travel with the lymph until drainage into the systemic blood circulation. 
 
 
 
 
 1.2.2 INTESTINAL LYMPHATIC DRUG TRANSPORT 
The majority of orally administered drugs gain access to the systemic 
circulation by direct absorption into the portal blood  (Porter and Charman, 
2001a). However, for some poorly water-soluble compounds, transport by 
way of the intestinal lymphatic system may provide an additional route of 
access into the systemic circulation (Porter and Charman, 2001a). Bypassing 
the liver, an alternative absorption pathway from the GI tract, provides an 
advantage over the portal blood route for avoidance of potential hepatic first-
pass metabolism, as discussed in section 1.1.3(c). It has been shown to 
enhance the bioavailability of a number of lipophilic drugs including the fat-
soluble vitamins (Dahan and Hoffman, 2007a), halofrantrine (Holm et al., 
2003), probucol (Palin and Wilson, 1984) and cyclosporine  (Ueda et al., 
1983). Lipid-based vehicles and the presence of food often enhance the oral 
bioavailability particularly of poorly water-soluble drugs. In some cases, the 
lymphatic system plays a significant role in this enhanced bioavailability. 
Therefore, it seems likely that the physiological processes of lipid digestion 
and absorption are relevant to this enhanced drug delivery. 
 
Lipid vehicles may enhance lymphatic transport of lipophilic compounds by 
stimulating the production of chylomicrons (O‟Driscoll, 2002). Lipophilic drugs 
enter the lymphatic system in association with the triglyceride core of the 
chylomicrons. In many cases, for example with the antimalarial drug 
halofantrine (log P 8.5, TG solubility 50 mg/ml), a strong correlation has been 
established between the degree of lymphatic drug transport and the TG 
content of the lymph  (Caliph et al., 2000).The importance of the physiological 
 process of lipid digestion in stimulating drug lymphatic transport has also 
been highlighted by Liu et al. (1995). Following administration of a milk fat 
globule membrane (MFGM) stabilized soybean emulsion, 19.2% of the dose 
of vitamin D3 was transported via the lymph, but the degree of transport 
dropped to 0.27% in rats with pancreatic duct ligation. On the other hand, 
when the MFGM emulsion was administered with bile salt and pancreatic 
lipase, the extent of lymphatic transport was increased again to 20.4%. 
Even with lipid-based formulations, various factors were found to influence 
the extent of lymphatic transport. These include the chemical structure, 
digestibility and dispersed state of the lipid vehicle. One of the earliest reports 
of intestinal lymphatic transport by Palin et al. (1982)  illustrated the 
importance of the digestibility of the vehicle on the extent of lymphatic 
transport. Arachis oil was found to significantly increase the lymphatic 
transport of dichlorodiphenyltrichloroethane (DDT) relative to non digestible 
liquid paraffin. In addition, long-chain unsaturated FAs were found to be more 
capable of enhancing lymphatic transport, and this has been attributed to 
their increased ability to stimulate chylomicron production (Charman et al., 
1986a, Palin et al., 1982). Besides that, a study by Porter et al. (1996a) 
supported the hypothesis that formulations of lipids as dispersed systems 
may promote the lymphatic transport. 
 
 
 1.3 LIPOSOMES 
1.3.1 INTRODUCTION 
Liposomes are naturally occurring self-assembled structures that can also be 
synthesized in the laboratory (Gómez-Hens and Fernández-Romero, 2005). 
They are composed of one or several lipid bilayers enclosing aqueous 
compartments and may range in size from tens of nanometers to tens of 
microns in diameter.  Liposomes are usually made of phospholipids, a class 
of amphiphilic molecules (possessing both hydrophilic and lipophilic 
properties) (Figure1.2) which is the main components of biological 
membranes. In aqueous medium, phospholipids arrange themselves into 
bilayers, by positioning their hydrophilic groups towards the surrounding 
aqueous medium, and their lipophilic chains towards the inner side of the 
bilayer.  
 
The potential of liposomes as drug delivery systems has been widely 
recognized (Torchilin, 2005, Vemuri and Rhodes, 1995, Woodle and 
Papahadjopoulos, 1989, Fendler and Romero, 1977, Gregoriadis, 1976). 
Drugs with widely varying lipophilicities can be encapsulated into liposomes, 
either in the phospholipid bilayer, in the encapsulated aqueous volume or at 
the bilayer interface (Sharma and Sharma, 1997) ( Figure 1.3). Hydrophobic 
drugs are incorporated into the lipid bilayers, while hydrophilic drugs are 
usually encapsulated in the aqueous compartments (Barenholz, 2003).  For 
drug delivery, liposomes can be formulated as a suspension, an aerosol,  or 
a semisolid preparation such as a gel or cream,  or a solid preparation like a 
dry powder (Lasic, 1998). 
  
 
 
 
 
 
Figure 1.2 Structural formula of a phospholipid molecule 
 
  
 
 
 
 
Figure 1.3 Distribution of drugs of different lipophilicities in liposomes 
(adapted from Sharma and Sharma, 1997)  
 
 
 
  Various routes of administration, namely parenteral, topical and oral, can be 
used for administration of liposomes (Betageri et al., 1993a). Many studies on 
liposomes as drug delivery systems employed the parenteral route. In 
addition to intravenous (i.v.) administration, liposomes have been 
administered via the intraperitoneal (i.p.), intramuscular (i.m.) and 
subcutaneous (s.c.) routes (Crommelin and Schreier, 1994, Zonneveld and 
Crommelin, 1988). Topical administration of liposomes includes application to 
the skin, eyes, lungs or body cavities. Thus, liposomes may be used for 
either local or systemic delivery of drugs (Betageri et al., 1993a).  Besides 
that, liposomes have been used successfully as an oral drug delivery system. 
Examples of drugs that showed improved bioavailability when administered 
orally in liposomal formulations include heparin (Jiao et al., 2002), insulin 
(Iwanagaa et al., 1997), cyclosporine (Al-Meshala et al., 1998), erythropoietin 
(Maitani et al., 2000a) and cefotaxime (Ling et al., 2006). 
 
 
1.3.2 CLASSIFICATION OF LIPOSOMES 
On the basis of their size and number of bilayers, liposomes can be classified 
as (Sharma and Sharma, 1997, Betageri et al., 1993b):  
 
(a) multilamellar vesicles (MLVs) 
MLVs usually consist of vesicles covering size range of 100 to 1000nm, each 
vesicle consisting five or more concentric bilayers. Vesicles, which are 
composed of less than five bilayers, are called oligo-lamellar vesicles. 
 
 (b) large unilamellar vesicles (LUVs) 
LUVs have diameters larger than 100nm in size and consist of one lipid 
bilayer.  Liposomes with sizes between 50 and 100nm are referred to as 
intermediate sized unilamellar vesicles. 
 
(c) small unilamellar vesicles (SUVs) 
SUVs are the lower sized liposomes. Their sizes depend on the ionic strength 
of the aqueous media and lipid composition, and are usually in the range 25 
to 50nm. They possess only one lipid bilayer. 
 
Besides classification based on the number of bilayers and size, liposomes 
can also be categorized in terms of their composition and mechanism of 
intracellular delivery (Sharma and Sharma, 1997). They are: 
 
(a) Conventional liposomes (CLs)  
CLs are composed of neutral and/or negatively charged phospholipids and 
cholesterol. As the contents of CLs are ultimately delivered to the lysosomes, 
CLs are therefore useful for reticuloendothelial system (RES) targeting. 
 
(b)  pH-sensitive liposomes 
They consist of phospholipids with either cholesteryl hemisuccinate or oleic 
acid. At low pH, they fuse with cell membranes and release their contents in 
cytoplasm. 
 
  
 (c) Cationic liposomes 
These usually compose of cationic lipid derivatives and neutral 
phospholipids. In most cases, they fuse with the cell membranes and are 
suitable for delivery of negatively charged macromolecules. 
 
(d) Long-circulating liposomes (LCLs) 
LCLs are also known as „Stealth Liposomes‟.  They consist of neutral 
phospholipids with high transition temperature (Tc) and cholesterol with 
hydrophilic surface coating. The surface coating sterically hinders a variety of 
interactions at the bilayer surface, so that the liposomes can escape the rapid 
uptake by macrophage cells of the RES, and thus circulate in the blood 
stream for a long time and passively target onto sites of tumors, infection and 
inflammation, often characterized by the presence of a leaky vasculature. 
 
(e)  Immunoliposomes 
These are CLs or LCLs with attached antibody or recognition sequence. They 
participate in cell-specific binding (targeting) and release their contents 
extracellularly near the target tissue. 
 
 
1.3.3 CHEMICAL CONSTITUENTS 
Liposomes can be prepared from a variety of lipids and other amphiphiles 
such as nonionic surfactants. The vesicles prepared from the latter are 
referred to as niosomes and are mainly used for topical application. 
Phospholipids, the most commonly used lipid for liposome preparation, can 
 be divided into four groups (van Winden et al., 1998, Barenholz and 
Crommelin, 1994): 
 
(a) Natural phospholipids 
The two main sources of natural phospholipids are eggs and soy beans. 
Natural phospholipids are usually present in a mixture of phospholipids with 
different chain length and varying degrees of unsaturation (New, 1990). 
Generally, plant-derived phospholipids have higher level of unsaturation in 
the fatty acyl chains compared to those of animal-derived. Natural 
phospholipids which are used for preparation of liposomes include 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin 
and phosphatidylinositol (PI).  
 
(b) Modified natural phospholipids 
These are natural phospholipids that are chemically modified to alter certain 
characteristics of the phospholipids. The acyl chains of natural phospholipids 
can be modified by partial or complete hydrogenation. Such modification 
reduces the degree of unsaturation (to different extents) and consequently 
improves the phospholipids‟ appearance and resistance to peroxidation 
(Barenholz and Crommelin, 1994). Another possible modification is 
conversion of head group of phospholipids with the aid of the enzyme 
phospholipase D. 
 
 (c) Semisynthetic phospholipids 
They are obtained by removing the acyl chains of natural phospholipids by 
chemical replacement with defined synthetic acyl chains (Lichtenberg and 
Barenholz, 1988). 
 
(d) Fully synthetic phospholipids 
These compounds are prepared via complete chemical synthetic pathways. 
Fully synthetic phospholipids have the advantage of a defined fatty acid 
composition and can be tailored to specific needs. 
 
Apart from phospholipids, other lipids used in liposome preparation include 
sterols, especially cholesterol. Cholesterol does not by itself form bilayer 
structures but can be incorporated into the phospholipid bilayer to provide 
greater stability (New, 1990). Cholesterol reduces the fluidity of the bilayer 
above the transition temperature, resulting in a corresponding reduction in 
the permeability to aqueous solutes. Cholesterol can be incorporated up to a 
level of 50 mol% (1:1 ratio), at which it displays its maximum stabilizing effect 
both in vitro and in vivo (New, 1990). 
 
 
1.3.4 METHODS OF PREPARATION 
Liposomes can be prepared according to three basic modes of preparation 
namely mechanical dispersion, solvent dispersion and detergent 
solubilization (Figure 1.4). 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
Figure 1.4 Classification of methods of liposome preparation (adapted from Jain 2001) 
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